Vitrolife (Sweden) Today
| VITR Stock | SEK 212.80 3.00 1.43% |
Performance0 of 100
| Odds Of DistressLess than 9
|
Vitrolife is selling for under 212.80 as of the 22nd of November 2024; that is 1.43 percent increase since the beginning of the trading day. The stock's last reported lowest price was 207.6. Vitrolife has less than a 9 % chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. Equity ratings for Vitrolife AB are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 23rd of October 2024 and ending today, the 22nd of November 2024. Click here to learn more.
Vitrolife AB , a medical device company, develops, produces, and markets products for assisted reproduction. Vitrolife AB was founded in 1981 and is headquartered in Gothenburg, Sweden. Vitrolife operates under Biotechnology classification in Sweden and is traded on Stockholm Stock Exchange. The company has 135.45 M outstanding shares. More on Vitrolife AB
Moving against Vitrolife Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Vitrolife Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Vitrolife's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Vitrolife or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| President | Rickard Ericsson |
| Business Concentration | Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) |
Vitrolife AB (VITR) is traded on Stockholm Exchange in Sweden and employs 1,073 people. The company currently falls under 'Large-Cap' category with a current market capitalization of 31.97 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Vitrolife's market, we take the total number of its shares issued and multiply it by Vitrolife's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Vitrolife AB operates under Biotechnology sector and is part of Health Care industry. The entity has 135.45 M outstanding shares.
Vitrolife AB has accumulated about 630.09 M in cash with 384.31 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.11.
Check Vitrolife Probability Of Bankruptcy
Ownership AllocationVitrolife AB shows a total of 135.45 Million outstanding shares. Vitrolife AB maintains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Vitrolife Ownership Details
Vitrolife AB Risk Profiles
Although Vitrolife's alpha and beta are two of the key measurements used to evaluate Vitrolife's performance over the market, the standard measures of volatility play an important role as well.
Vitrolife Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Vitrolife without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Latest Portfolios Now
Latest PortfoliosQuick portfolio dashboard that showcases your latest portfolios |
| All Next | Launch Module |
Vitrolife Corporate Management
Elected by the shareholders, the Vitrolife's board of directors comprises two types of representatives: Vitrolife inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Vitrolife. The board's role is to monitor Vitrolife's management team and ensure that shareholders' interests are well served. Vitrolife's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Vitrolife's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Daniel Forss | VP Consumables | Profile | |
| Claus Bisgaard | VP Technologies | Profile | |
| Ricardo Capella | VP Services | Profile | |
| Karin Russberg | VP Sustainability | Profile | |
| Patrik Tolf | Chief Officer | Profile | |
| Thomas MSc | Pres CEO | Profile |
Additional Tools for Vitrolife Stock Analysis
When running Vitrolife's price analysis, check to measure Vitrolife's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vitrolife is operating at the current time. Most of Vitrolife's value examination focuses on studying past and present price action to predict the probability of Vitrolife's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vitrolife's price. Additionally, you may evaluate how the addition of Vitrolife to your portfolios can decrease your overall portfolio volatility.